Goodwin advised Aptinyx on the deal
Aptinyx Inc. finalized its $70 million Series B financing to fund the advancement of its expanding clinical stage pipeline. The funds will support clinical studies of Aptinyx’s drug candidates, including NYX-2925, in development for the treatment of neuropathic pain, and NYX-783, in development as a therapy for post-traumatic stress disorder (PTSD). The company also plans to advance a third proprietary compound into the clinic in 2018, initiate development programs in new indications, and continue discovery of additional novel, small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors.
The financing was led by Bain Capital Life Sciences. Additional new investors include Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management and Rock Springs Capital. Existing investors also participated in the Series B round, including New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O’Keefe & Company, and Northwestern University.
Aptinyx is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system.
The Goodwin team was led by partners Mitchell Bloom (Picture) and Caitlin Murray and included associates Xing Yan and Gabriela Morales-Rivera.
Law Firms: Goodwin Procter;
Clients: Aptinyx Inc.;